The FDA announced yesterday that it’s convening its Vaccines and Related Biological Products (VRBPAC) to consider the strain composition for vaccines “for the 2023-2024 vaccination campaign.” Although such an annual cadence has previously been discussed, this meeting will be the first where VRBPAC members explicitly consider SARS-CoV-2 strains for vaccination on an annual basis.
Background
On June 15, 2023, the FDA’s Vaccines and Related Biologic Products Advisory Committee (VRBPAC) will meet to discuss which strain, or strains, should be included in Covid-19 vaccines for what the FDA is describing as a “2023-2024 vaccination campaign.”
Fill out the form to read the full article.
